This Best Practices Report intends to bring our experience in European Industrial Doctorates (EID) to other consortia with awarded EID Programmes ongoing and to institutions considering applying for funding to this scheme.
This Best Practices Report intends to bring our experience in European Industrial Doctorates (EID)
to other consortia with awarded EID Programmes ongoing and to institutions consideringapplying
for funding to this scheme.
EID is a sub-scheme of Marie Curie Initial Training Networks (ITN) within FP7, and OpenMedChem
was one of the projects awarded within the first call (FP7-PEOPLE-2012-ITN).
Since there are several reports and handbooks publicly available on general project management
and reporting aspects of FP7 and H2020, this deliverable intends to focus only on the experienced
gained in the particularities of the EID scheme. Of course many of the aspects listed can be applied
to other collaborative projects.
The report can be donwloaded here: Best Practices Report
The fellows will move to GSK's Tres Cantos site in Spain for the second stage of the OpenMedChem project.
Their goals are to further optimise anti-mycobacterial compounds and to maximally profit from the technological opportunities offered in an industrial drug discovery environment.
A strong emphasis will be put on the extended biological investigation of the produced small compounds.
The fellows presented their first year scientific results at the GSK DDW site in Madrid.
back (left to right): Maciej Rogacki, Elena Lopez Santos, Eleni Pitta and Julia Castro-Pichel; front (left to right) Fraser Cunningham, Robert Bates and Pieter Van der Veken
We are delighted to announce that OpenMedChem selected three Early Stage Researchers: Olga Balabon form Ukraine, Elena Pitta from Greece and Maciej Rogacki from Poland. They were chosen out of more than 150 candidates. The fellows have immediately taken up their project and the first compounds have been synthesized.
left to right: Olga Balabon, Maciej Rogacki and Eleni Pitta
The conference featured a discussion of target and compound discovery, new potential antituberculosis compounds which are in development, clinical trial design and early trial results, and alternative approaches to tuberculosis treatment.
Dr. David Barros, TB Drug Discovery Director at GSK DDW, was appointed Vice-chairman and Chairman for the 2013 and 2015 Conferences, respectively. More information on the Conference's website
left to right: Maciej Rogacki, Robert Bates, Eleni Pitta, Lluís Ballell, Pieter Van der Veken, Olga Balabon and David Barros